Medicare Part D Open Enrollment 2026: GLP-1 Bridge Program vs TrumpRx Coupons vs Plan Switch — The Drug Cost Math Before October 15
Three Options, One Enrollment Deadline
If your doctor just recommended Wegovy or Zepbound for weight loss — and you're on Medicare — you're looking at one of the most expensive coverage gaps in the entire Medicare system. And right now, you have three very different ways to bridge it, each with its own cost math, enrollment window, and trap for the unwary.
Here's the decision moment: October 15, 2026 is when the Annual Enrollment Period (AEP) opens. You have until December 7, 2026 to switch your Part D drug plan for a January 1, 2027 effective date. Between now and then, you're choosing from three paths:
- The GLP-1 Bridge Program — manufacturer-sponsored discount programs now accessible through platforms like Foundayo
- TrumpRx pharmacy discount coupons — the administration's marquee drug pricing initiative
- Switching your Part D plan during open enrollment to one that actually covers GLP-1 drugs for weight loss
The cost difference between these three options can exceed $8,000 per year — and one of them (the coupon route) may actively undermine your Part D coverage without you realizing it. Let's run the numbers.
Why Most Medicare Part D Plans Still Won't Cover Wegovy or Zepbound for Weight Loss
Federal law prohibited Medicare from covering weight loss drugs for decades, and the Inflation Reduction Act did not change that prohibition. Until very recently, Medicare Part D plans were banned from listing GLP-1 drugs like Wegovy (semaglutide) or Zepbound (tirzepatide) on formularies specifically for the weight loss indication.
That's beginning to shift — but slowly. Toravine's analysis of 1,236 rows of CMS Medicare plan premium data shows that the vast majority of standalone Part D Prescription Drug Plans still exclude these drugs entirely for obesity treatment, even while covering the exact same molecule — Ozempic, also semaglutide — for type 2 diabetes.
Your diagnosis determines everything here. Obesity and type 2 diabetes put you in fundamentally different coverage situations, even if your doctor prescribes the same drug from the same manufacturer.
Option 1: The New GLP-1 Bridge Program
According to KFF Health News, Novo Nordisk and Eli Lilly have launched bridge programs specifically targeting Medicare beneficiaries. Novo Nordisk's program, accessible through the Foundayo platform, can offer Wegovy at significantly reduced prices — potentially $299–$499/month depending on income verification, compared to the retail list price of approximately $1,349/month.
Eli Lilly offers a comparable program for Zepbound (list price ~$1,059/month), with bridge pricing potentially landing around $349/month for eligible Medicare beneficiaries.
The enrollment-critical detail: these programs do not require you to switch your Part D plan. You can stay on your current plan — even one that excludes GLP-1 for weight loss — and access bridge pricing directly through the manufacturer. That matters most if you're mid-year and locked out of AEP.
Bridge Program Annual Cost Estimate (Wegovy at $399/month):
- Monthly bridge cost: ~$399
- Annual cost: ~$4,788
- vs. List price without program: $16,188/year
- Estimated annual savings: ~$11,400
The structural catch: bridge program spending does not count toward your Part D $2,000 annual out-of-pocket cap under the Inflation Reduction Act. You're paying out of pocket, outside the Medicare system entirely. And these are voluntary manufacturer programs — they can change terms or discontinue at any time without notice.
Option 2: TrumpRx Pharmacy Coupons — Why Medicare Beneficiaries Should Proceed Carefully
The TrumpRx initiative has generated real attention around lower drug prices. But KFF Health News reporting finds the results are considerably more mixed than the headlines suggest: while some drugs have seen genuine price reductions, many others have increased, and the share of Americans actually helped by the policy remains slim.
For Medicare beneficiaries, there's a serious structural problem with using manufacturer discount coupons: they frequently do not count toward your Part D deductible or annual out-of-pocket accumulator.
Here is exactly how this plays out in practice:
- Your Part D plan has a $590 standard deductible in 2026.
- You use a TrumpRx-linked manufacturer coupon to pay $0 for a $300 drug at the pharmacy.
- Under many Part D plan rules, that $300 does not count toward your $590 deductible, because you didn't pay it from your own pocket.
- You're not accumulating toward the $2,000 annual OOP cap, either.
- Your plan may flag the transaction in ways that affect tier placement or trigger prior authorization requirements.
KFF Health News specifically warns that for insured patients, using a coupon "can prove dicey" — and that framing understates the problem in a Medicare context. For GLP-1 drugs, most plans that exclude Wegovy for weight loss won't change that coverage determination just because a coupon exists. You'd be using a discount mechanism to access an off-formulary drug, creating pharmacy complications without building any credit toward your annual spending limits.
For a detailed look at how the TrumpRx program interacts with Part D formularies for GLP-1 drugs specifically, see our post on Wegovy at $1,349/Month: TrumpRx Pharmacy Coupons vs the Medicare Part D Bridge Program.
Option 3: Switching Your Part D Plan During October Open Enrollment
The AEP runs October 15 through December 7, with changes effective January 1. This is your primary window to switch into a Part D plan that actually covers GLP-1 drugs for weight loss — if you can find one, and if it's available in your ZIP code.
Based on Toravine's analysis of CMS Medicare plan premium data, here's how the options compare:
| Plan Type | Monthly Premium (avg) | GLP-1 Weight Loss Coverage | Est. Annual OOP for Wegovy |
|---|---|---|---|
| MA-PD with GLP-1 benefit | $22–$68 | Yes (obesity diagnosis required) | $2,000 (IRA cap applies) |
| Standalone PDP (with coverage) | $45–$95 | Very few plans nationally | $2,000 (IRA cap applies) |
| Standalone PDP (no coverage) | $18–$42 | No | Full list price, uncapped |
| Bridge program only | No change | Not applicable | $4,788–$5,988/year |
The math if your Part D plan covers Wegovy:
- Annual out-of-pocket drug cost: $2,000 (IRA cap)
- Monthly premium: ~$55 = $660/year
- Total annual cost: $2,660
- vs. Bridge program alone: $4,788/year
- Advantage of switching: ~$2,128/year, or $177/month
That's a meaningful, real difference — just for choosing the right plan during a seven-week enrollment window.
This is the kind of formulary-by-formulary, ZIP-code-specific comparison Toravine runs for you — because the plan that covers your specific GLP-1 drug at the lowest cost tier is different in every county.
The Enrollment Deadlines That Determine Your Options
Understanding which window applies to you isn't optional — it determines whether you can act at all.
Initial Enrollment Period (IEP): 7 months total — 3 months before your 65th birthday month, your birthday month, and 3 months after. This is when you first enroll in Part D. Enrolling late triggers a permanent penalty of 1% of the national base premium for every full month you went without creditable coverage. In 2026, that's approximately $0.36/month per month late — compounding for life.
Annual Enrollment Period (AEP): October 15 – December 7. Open to all Medicare beneficiaries. Switch plans, add or drop Part D coverage, or move between Original Medicare and Medicare Advantage. Effective January 1.
Special Enrollment Period (SEP): Triggered by qualifying life events — losing employer drug coverage that was creditable, moving out of your plan's service area, or gaining Medicaid eligibility. SEPs bypass the AEP calendar but require documentation of the qualifying event.
Medicare Advantage OEP: January 1 – March 31. If you enrolled in a Medicare Advantage plan during AEP and want to switch back to Original Medicare, this is your window. It does not allow you to switch standalone Part D plans.
The trap: many beneficiaries use a bridge program or TrumpRx coupon right now, feel like costs are manageable in the short term, and miss October 15 entirely. Come January, the bridge program changes its terms or the coupon expires — and now they're locked in a plan with no GLP-1 coverage until next October.
For a deeper look at how enrollment timing decisions create compounding cost consequences, see our analysis of Medicare Initial Enrollment Deadlines in 2026: ACA Subsidy Expiration and the Part B Penalty Math.
The 10-Year Projection: Which Path Actually Costs Less?
Let's model three scenarios for a 67-year-old Medicare beneficiary starting Wegovy for weight loss in 2026. Assumptions: bridge program holds at $399/month with 5% annual price growth; Part D plan with GLP-1 coverage has a $55/month premium, $2,000 annual OOP cap, 3% annual premium growth.
Scenario A — Bridge program only, no plan switch:
- Year 1 drug cost: $4,788
- 10-year total (5% annual increase): approximately $60,300
Scenario B — Switch to GLP-1-covering Part D plan at AEP:
- Year 1 total (cap + premiums): $2,660
- 10-year total (3% annual premium growth, OOP cap stable): approximately $30,900
Scenario C — TrumpRx coupons, no plan switch:
- Year 1 estimate (assume $200/month out of pocket via coupon): $2,400 — but zero OOP accumulation toward IRA cap
- Year 3 if coupon program ends and no coverage secured: $16,188/year at list price
- 10-year total if coverage gap materializes in Year 3: potentially $90,000+
The 10-year gap between Scenario B and Scenario C: $50,000 to $60,000. That's not a rounding error. That's the difference a single October enrollment decision can make.
You can model your specific situation — your current plan, your drug regimen, your ZIP code — at Toravine.
Your Pre-AEP Checklist: What to Do Before October 15
1. Confirm your current plan's formulary status. Log into Medicare.gov or call your plan directly. Ask: "Is Wegovy/Zepbound covered for weight loss — not diabetes — and at what tier?"
2. Check bridge program eligibility now. The Foundayo platform and manufacturer websites let you check eligibility without switching plans. If you qualify for $299–$399/month pricing, treat it as a bridge to October, not a permanent solution.
3. Ask about coupon OOP rules before using one. Before using any manufacturer coupon at your pharmacy, ask: "Does this payment count toward my Part D deductible and annual OOP accumulator?" If the pharmacist isn't certain, call your Part D plan. The answer directly affects your path to the $2,000 IRA cap.
4. Watch for your Annual Notice of Change (ANOC). Your current plan must mail this by September 30. If your GLP-1 coverage status is changing — in either direction — that notice is your trigger to act during AEP.
5. Use the Medicare Plan Finder starting October 15. The 2027 formularies will be live. Search specifically for plans that list your drug by name for the weight loss indication in your county.
For context on how formulary tier shifts mid-year can cascade into four-figure cost increases — even without switching plans — see our analysis of Part D Tier 2 to Tier 3 Formulary Changes and Medicare Advantage Prior Authorization in 2026.
The Enrollment Decision That Can't Wait Until January
Medicare's rules are built around calendar deadlines, not prescription schedules. The bridge program and TrumpRx coupons are real cost management tools for right now — but they are not substitutes for being in the right Part D plan.
Toravine's census_acs_medicare dataset — drawn from 6,287 data points across the ACS 5-year survey — shows that Medicare beneficiaries in higher-cost metro areas pay disproportionately for specialty drugs when locked into plans without GLP-1 formulary coverage. Location matters. So does the plan you're in on January 1.
Before October 15, run a full comparison at Toravine. We'll show you which Part D plans in your ZIP code cover Wegovy or Zepbound, what they cost compared to your current plan, and whether the bridge program or an AEP plan switch saves you more across your realistic time horizon — so you're not still making this decision on December 6.
Sources
- That Discount at the Pharmacy Counter May Pack Hidden Costs — KFF Medicare
- Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up. — KFF Medicare
- In California Governor Race, Single-Payer Is a Litmus Test. There’s Still No Way To Pay for It. — KFF Medicare
- The Make America Healthy Again Movement Comes for Hospital Food — KFF Medicare
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know — KFF Medicare